Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Sajid Khan, Yonghan He, Xuan Zhang, et al.
Oncogene (2020) Vol. 39, Iss. 26, pp. 4909-4924
Open Access | Times Cited: 189

Showing 1-25 of 189 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1824
An expanded lexicon for the ubiquitin code
Ivan Đikić, Brenda A. Schulman
Nature Reviews Molecular Cell Biology (2022) Vol. 24, Iss. 4, pp. 273-287
Open Access | Times Cited: 223
E3 ubiquitin ligases: styles, structures and functions
Quan Yang, Jinyao Zhao, Dan Chen, et al.
Molecular Biomedicine (2021) Vol. 2, Iss. 1
Open Access | Times Cited: 219
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 184
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 147
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Jianwei Qu, Haimeng Yan, Yifan Hou, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 141
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Dongwen Lv, Pratik Pal, Xingui Liu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 106
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 98
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 73
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 71
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 46
Discovery of Nanomolar DCAF1 Small Molecule Ligands
Alice Shi Ming Li, Serah Kimani, Brian J. Wilson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 5041-5060
Open Access | Times Cited: 44
PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Liang Shen, Bo Wang, ShaoPeng Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 922-951
Closed Access | Times Cited: 16
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martín-Acosta, Xiangshu Xiao
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112993-112993
Open Access | Times Cited: 104
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 91
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Yufeng Xiao, Jia Wang, Lisa Zhao, et al.
Chemical Communications (2020) Vol. 56, Iss. 68, pp. 9866-9869
Open Access | Times Cited: 91
Druggable genome and precision medicine in cancer: current challenges
Camille Dupont, Kristina Riegel, Malvika Pompaiah, et al.
FEBS Journal (2021) Vol. 288, Iss. 21, pp. 6142-6158
Open Access | Times Cited: 69
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
Lin Zhang, Ling Li, Xia Wang, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 66-79
Open Access | Times Cited: 67
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 63
The rise of covalent proteolysis targeting chimeras
Ronen Gabizon, Nir London
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 24-33
Closed Access | Times Cited: 61
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
Gabriel LaPlante, Wei Zhang
Cancers (2021) Vol. 13, Iss. 12, pp. 3079-3079
Open Access | Times Cited: 57
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top